The FDA has approved three such drugs for MS. Ocrelizumab (Ocrevus) treats relapsing forms of MS, including: Clinically isolated syndrome Relapsing-remitting MS Active secondary progressive MS in ...

Roche has said it plans to UK price its latest multiple sclerosis drug Ocrevus in line with its close rival from Novartis - aiming to undercut some established rivals. Approved in Europe earlier ...

Ocrelizumab (Ocrevus), is a drug that sticks to B cells and destroys them. That helps prevent MS damage and symptoms. It’s approved by the FDA for: Clinically isolated syndrome Relapsing ...

With Ocrevus, patients need to stay in hospital ... Extavia and Glatopa (glatiramer acetate), a generic of Teva’s Copaxone.

Wanda was taking Copaxone to treat her M.S. until Oct. 11 ... As the availability of Ocrevus Zunuvo continues to increase across the country, Josh Weber, UVA Health’s director of specialty ...

Copaxone (glatiramer acetate) is a brand-name injection that’s prescribed for certain forms of multiple sclerosis. The cost of the drug, with and without insurance, can depend on several factors ...

The first $425-million tranche of the settlement covers claims that Teva leveraged two assistance foundations to fund patients’ copays for the blockbuster multiple sclerosis (MS) drug Copaxone ...

Ocrevus is a medicine commonly used to treat primary progressive MS, but it can take up to four hours to receive intravenously. A new version called “Ocrevus Zunovo” was recently approved by ...

Roche has secured approval from the US Food and Drug Administration (FDA) for Ocrevus Zunovo (ocrelizumab and ...

The commission argues that Teva "abused its dominant position" in the glatiramer acetate market with its blockbuster drug Copaxone by artificially extending its patent lifecycle and hindering ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. The European Commission has fined Teva, the world’s largest generic drugmaker, €462.6mn for hindering ...